Penumbra, Inc. (PEN) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospita...
Penumbra, Inc.'s revenue increased 17.5% year over year, from $1.19B to $1.40B.
Net income increased 1168.1% over the same period, from $14.0M to $177.7M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 433% in total.
Operating cash flow grew 41.7% to $238.7M.
Penumbra, Inc. maintains a healthy net profit margin of 12.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $299.4M+7.4% | $-60.2M | $162.8M | $-81.0M | $22.6M | $1.53B | N/A | $1.16B |
| Q3 FY2024 | $301.0M+0.5% | $29.5M | $200.3M | $35.4M | $56.5M | $1.48B | N/A | $1.10B |
| Q4 FY2024 | $315.5M+4.8% | $33.7M | $210.7M | $42.8M | $51.1M | $1.53B | N/A | $1.15B |
| Q1 FY2025 | $324.1M+2.7% | $39.2M | $215.9M | $40.4M | $49.0M | $1.59B | N/A | $1.21B |
| Q2 FY2025 | $339.5M+4.7% | $45.3M | $224.0M | $40.8M | $44.9M | $1.67B | N/A | $1.29B |
| Q3 FY2025 | $354.7M+4.5% | $45.9M | $240.4M | $48.8M | $58.3M | $1.74B | N/A | $1.36B |
| Q4 FY2025 | $385.4M+8.7% | $47.3M | $262.1M | $59.2M | $86.5M | $1.83B | N/A | $1.43B |
| Q1 FY2026 | $374.8M-2.8% | $32.6M | $253.4M | $38.2M | $87.0M | $1.90B | N/A | $1.47B |
Balance Sheet Summary (Latest Period)
Penumbra, Inc. (PEN) Financial Statements & Revenue History
Penumbra, Inc. (PEN) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $319.72 with a market capitalization of $13. This page provides 41 historical financial statements for Penumbra, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Penumbra, Inc. reported revenue of $1.4 billion, representing 17.5% year-over-year growth. The net profit margin of 12.7% indicates moderate profitability..
PEN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Penumbra, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether PEN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track PEN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Penumbra, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of PEN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use PEN Financial Data
Investors use Penumbra, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare PEN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how PEN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View PEN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Penumbra, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.PEN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.